CN111265661A - 一种医疗碳棒芯料组分 - Google Patents
一种医疗碳棒芯料组分 Download PDFInfo
- Publication number
- CN111265661A CN111265661A CN202010220737.XA CN202010220737A CN111265661A CN 111265661 A CN111265661 A CN 111265661A CN 202010220737 A CN202010220737 A CN 202010220737A CN 111265661 A CN111265661 A CN 111265661A
- Authority
- CN
- China
- Prior art keywords
- oxide
- metal
- carbon rod
- core material
- rod core
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 title claims abstract description 44
- 229910052799 carbon Inorganic materials 0.000 title claims abstract description 40
- 239000011162 core material Substances 0.000 title claims abstract description 24
- 229910044991 metal oxide Inorganic materials 0.000 claims abstract description 11
- 150000004706 metal oxides Chemical class 0.000 claims abstract description 11
- 229910001512 metal fluoride Inorganic materials 0.000 claims abstract description 10
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 claims abstract description 9
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims abstract description 7
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims abstract description 7
- 239000011591 potassium Substances 0.000 claims abstract description 7
- 229910052700 potassium Inorganic materials 0.000 claims abstract description 7
- 229910052717 sulfur Inorganic materials 0.000 claims abstract description 7
- 239000011593 sulfur Substances 0.000 claims abstract description 7
- 229910052804 chromium Inorganic materials 0.000 claims abstract description 6
- 239000011651 chromium Substances 0.000 claims abstract description 6
- XGZVUEUWXADBQD-UHFFFAOYSA-L lithium carbonate Chemical compound [Li+].[Li+].[O-]C([O-])=O XGZVUEUWXADBQD-UHFFFAOYSA-L 0.000 claims abstract description 6
- 229910052808 lithium carbonate Inorganic materials 0.000 claims abstract description 6
- 229910052761 rare earth metal Inorganic materials 0.000 claims abstract description 6
- 150000003839 salts Chemical class 0.000 claims abstract description 6
- 239000000341 volatile oil Substances 0.000 claims abstract description 6
- 235000009051 Ambrosia paniculata var. peruviana Nutrition 0.000 claims abstract description 5
- 235000003097 Artemisia absinthium Nutrition 0.000 claims abstract description 5
- 240000001851 Artemisia dracunculus Species 0.000 claims abstract description 5
- 235000017731 Artemisia dracunculus ssp. dracunculus Nutrition 0.000 claims abstract description 5
- 235000003261 Artemisia vulgaris Nutrition 0.000 claims abstract description 5
- 239000001138 artemisia absinthium Substances 0.000 claims abstract description 5
- 239000006229 carbon black Substances 0.000 claims abstract description 5
- 229910001510 metal chloride Inorganic materials 0.000 claims abstract description 5
- 150000002910 rare earth metals Chemical class 0.000 claims abstract description 5
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 claims abstract description 5
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims abstract description 4
- 229910052751 metal Inorganic materials 0.000 claims abstract description 4
- 239000002184 metal Substances 0.000 claims abstract description 4
- 239000001103 potassium chloride Substances 0.000 claims abstract description 4
- 235000011164 potassium chloride Nutrition 0.000 claims abstract description 4
- 229910002804 graphite Inorganic materials 0.000 claims abstract description 3
- 239000010439 graphite Substances 0.000 claims abstract description 3
- AMWRITDGCCNYAT-UHFFFAOYSA-L hydroxy(oxo)manganese;manganese Chemical compound [Mn].O[Mn]=O.O[Mn]=O AMWRITDGCCNYAT-UHFFFAOYSA-L 0.000 claims description 12
- IATRAKWUXMZMIY-UHFFFAOYSA-N strontium oxide Chemical compound [O-2].[Sr+2] IATRAKWUXMZMIY-UHFFFAOYSA-N 0.000 claims description 12
- QPLDLSVMHZLSFG-UHFFFAOYSA-N Copper oxide Chemical compound [Cu]=O QPLDLSVMHZLSFG-UHFFFAOYSA-N 0.000 claims description 10
- 239000005751 Copper oxide Substances 0.000 claims description 10
- 229910000431 copper oxide Inorganic materials 0.000 claims description 10
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 claims description 8
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 claims description 8
- QVQLCTNNEUAWMS-UHFFFAOYSA-N barium oxide Chemical compound [Ba]=O QVQLCTNNEUAWMS-UHFFFAOYSA-N 0.000 claims description 8
- MRELNEQAGSRDBK-UHFFFAOYSA-N lanthanum(3+);oxygen(2-) Chemical compound [O-2].[O-2].[O-2].[La+3].[La+3] MRELNEQAGSRDBK-UHFFFAOYSA-N 0.000 claims description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 6
- 229910001952 rubidium oxide Inorganic materials 0.000 claims description 6
- CWBWCLMMHLCMAM-UHFFFAOYSA-M rubidium(1+);hydroxide Chemical compound [OH-].[Rb+].[Rb+] CWBWCLMMHLCMAM-UHFFFAOYSA-M 0.000 claims description 6
- BRPQOXSCLDDYGP-UHFFFAOYSA-N calcium oxide Chemical compound [O-2].[Ca+2] BRPQOXSCLDDYGP-UHFFFAOYSA-N 0.000 claims description 5
- ODINCKMPIJJUCX-UHFFFAOYSA-N calcium oxide Inorganic materials [Ca]=O ODINCKMPIJJUCX-UHFFFAOYSA-N 0.000 claims description 5
- 239000000292 calcium oxide Substances 0.000 claims description 5
- 229910000428 cobalt oxide Inorganic materials 0.000 claims description 5
- IVMYJDGYRUAWML-UHFFFAOYSA-N cobalt(ii) oxide Chemical compound [Co]=O IVMYJDGYRUAWML-UHFFFAOYSA-N 0.000 claims description 5
- 229910000450 iodine oxide Inorganic materials 0.000 claims description 5
- AFSVSXMRDKPOEW-UHFFFAOYSA-N oxidoiodine(.) Chemical compound I[O] AFSVSXMRDKPOEW-UHFFFAOYSA-N 0.000 claims description 5
- WGLPBDUCMAPZCE-UHFFFAOYSA-N Trioxochromium Chemical compound O=[Cr](=O)=O WGLPBDUCMAPZCE-UHFFFAOYSA-N 0.000 claims description 4
- XHCLAFWTIXFWPH-UHFFFAOYSA-N [O-2].[O-2].[O-2].[O-2].[O-2].[V+5].[V+5] Chemical compound [O-2].[O-2].[O-2].[O-2].[O-2].[V+5].[V+5] XHCLAFWTIXFWPH-UHFFFAOYSA-N 0.000 claims description 4
- QCCDYNYSHILRDG-UHFFFAOYSA-K cerium(3+);trifluoride Chemical compound [F-].[F-].[F-].[Ce+3] QCCDYNYSHILRDG-UHFFFAOYSA-K 0.000 claims description 4
- 229910000423 chromium oxide Inorganic materials 0.000 claims description 4
- PQXKHYXIUOZZFA-UHFFFAOYSA-M lithium fluoride Chemical compound [Li+].[F-] PQXKHYXIUOZZFA-UHFFFAOYSA-M 0.000 claims description 4
- FUJCRWPEOMXPAD-UHFFFAOYSA-N lithium oxide Chemical compound [Li+].[Li+].[O-2] FUJCRWPEOMXPAD-UHFFFAOYSA-N 0.000 claims description 4
- 229910001947 lithium oxide Inorganic materials 0.000 claims description 4
- 239000000395 magnesium oxide Substances 0.000 claims description 4
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 claims description 4
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 claims description 4
- 229910000476 molybdenum oxide Inorganic materials 0.000 claims description 4
- PQQKPALAQIIWST-UHFFFAOYSA-N oxomolybdenum Chemical compound [Mo]=O PQQKPALAQIIWST-UHFFFAOYSA-N 0.000 claims description 4
- HYXGAEYDKFCVMU-UHFFFAOYSA-N scandium oxide Chemical compound O=[Sc]O[Sc]=O HYXGAEYDKFCVMU-UHFFFAOYSA-N 0.000 claims description 4
- JPJALAQPGMAKDF-UHFFFAOYSA-N selenium dioxide Chemical compound O=[Se]=O JPJALAQPGMAKDF-UHFFFAOYSA-N 0.000 claims description 4
- ZCUFMDLYAMJYST-UHFFFAOYSA-N thorium dioxide Chemical compound O=[Th]=O ZCUFMDLYAMJYST-UHFFFAOYSA-N 0.000 claims description 4
- 229910001935 vanadium oxide Inorganic materials 0.000 claims description 4
- 239000011787 zinc oxide Substances 0.000 claims description 4
- ORTQZVOHEJQUHG-UHFFFAOYSA-L copper(II) chloride Chemical compound Cl[Cu]Cl ORTQZVOHEJQUHG-UHFFFAOYSA-L 0.000 claims description 3
- 239000011780 sodium chloride Substances 0.000 claims description 3
- 229910001631 strontium chloride Inorganic materials 0.000 claims description 3
- AHBGXTDRMVNFER-UHFFFAOYSA-L strontium dichloride Chemical compound [Cl-].[Cl-].[Sr+2] AHBGXTDRMVNFER-UHFFFAOYSA-L 0.000 claims description 3
- WDIHJSXYQDMJHN-UHFFFAOYSA-L barium chloride Chemical compound [Cl-].[Cl-].[Ba+2] WDIHJSXYQDMJHN-UHFFFAOYSA-L 0.000 claims description 2
- 229910001626 barium chloride Inorganic materials 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims description 2
- FVRNDBHWWSPNOM-UHFFFAOYSA-L strontium fluoride Chemical compound [F-].[F-].[Sr+2] FVRNDBHWWSPNOM-UHFFFAOYSA-L 0.000 claims description 2
- 229910001637 strontium fluoride Inorganic materials 0.000 claims description 2
- NDLPOXTZKUMGOV-UHFFFAOYSA-N oxo(oxoferriooxy)iron hydrate Chemical compound O.O=[Fe]O[Fe]=O NDLPOXTZKUMGOV-UHFFFAOYSA-N 0.000 claims 1
- 239000011573 trace mineral Substances 0.000 abstract description 5
- 235000013619 trace mineral Nutrition 0.000 abstract description 5
- 230000000144 pharmacologic effect Effects 0.000 abstract description 3
- 229940126680 traditional chinese medicines Drugs 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 24
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 11
- 238000001228 spectrum Methods 0.000 description 11
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 8
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 230000006870 function Effects 0.000 description 7
- 229910052744 lithium Inorganic materials 0.000 description 7
- 230000004060 metabolic process Effects 0.000 description 7
- 238000010521 absorption reaction Methods 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 230000002708 enhancing effect Effects 0.000 description 6
- JEIPFZHSYJVQDO-UHFFFAOYSA-N ferric oxide Chemical compound O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 230000001276 controlling effect Effects 0.000 description 5
- 230000036541 health Effects 0.000 description 5
- 230000036039 immunity Effects 0.000 description 5
- 230000001737 promoting effect Effects 0.000 description 5
- 210000003491 skin Anatomy 0.000 description 5
- 229910052712 strontium Inorganic materials 0.000 description 5
- CIOAGBVUUVVLOB-UHFFFAOYSA-N strontium atom Chemical compound [Sr] CIOAGBVUUVVLOB-UHFFFAOYSA-N 0.000 description 5
- 206010061218 Inflammation Diseases 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000000988 bone and bone Anatomy 0.000 description 4
- 210000001185 bone marrow Anatomy 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 230000003394 haemopoietic effect Effects 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 229910001414 potassium ion Inorganic materials 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 229910052701 rubidium Inorganic materials 0.000 description 4
- IGLNJRXAVVLDKE-UHFFFAOYSA-N rubidium atom Chemical compound [Rb] IGLNJRXAVVLDKE-UHFFFAOYSA-N 0.000 description 4
- 239000013589 supplement Substances 0.000 description 4
- 230000000007 visual effect Effects 0.000 description 4
- 208000024172 Cardiovascular disease Diseases 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 208000001132 Osteoporosis Diseases 0.000 description 3
- 230000000844 anti-bacterial effect Effects 0.000 description 3
- 208000006673 asthma Diseases 0.000 description 3
- 230000007812 deficiency Effects 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 210000003743 erythrocyte Anatomy 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 230000011132 hemopoiesis Effects 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 229910052742 iron Inorganic materials 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 201000004384 Alopecia Diseases 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 206010010774 Constipation Diseases 0.000 description 2
- 201000004624 Dermatitis Diseases 0.000 description 2
- 208000035240 Disease Resistance Diseases 0.000 description 2
- 102000008857 Ferritin Human genes 0.000 description 2
- 108050000784 Ferritin Proteins 0.000 description 2
- 238000008416 Ferritin Methods 0.000 description 2
- 102000001554 Hemoglobins Human genes 0.000 description 2
- 108010054147 Hemoglobins Proteins 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- ZOKXTWBITQBERF-UHFFFAOYSA-N Molybdenum Chemical compound [Mo] ZOKXTWBITQBERF-UHFFFAOYSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 208000003251 Pruritus Diseases 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 231100000360 alopecia Toxicity 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 230000003266 anti-allergic effect Effects 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 208000010668 atopic eczema Diseases 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 210000000748 cardiovascular system Anatomy 0.000 description 2
- 230000011748 cell maturation Effects 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 208000000718 duodenal ulcer Diseases 0.000 description 2
- 239000010440 gypsum Substances 0.000 description 2
- 229910052602 gypsum Inorganic materials 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 230000007803 itching Effects 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 239000011785 micronutrient Substances 0.000 description 2
- 235000013369 micronutrients Nutrition 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 229910052750 molybdenum Inorganic materials 0.000 description 2
- 239000011733 molybdenum Substances 0.000 description 2
- 239000004050 mood stabilizer Substances 0.000 description 2
- 229940127237 mood stabilizer Drugs 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 238000001126 phototherapy Methods 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- -1 rare earth fluoride Chemical class 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 230000002936 tranquilizing effect Effects 0.000 description 2
- 230000007704 transition Effects 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 206010000234 Abortion spontaneous Diseases 0.000 description 1
- 206010063409 Acarodermatitis Diseases 0.000 description 1
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 241001251371 Betula chinensis Species 0.000 description 1
- 208000035985 Body Odor Diseases 0.000 description 1
- 206010065687 Bone loss Diseases 0.000 description 1
- 206010055000 Bromhidrosis Diseases 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 208000010228 Erectile Dysfunction Diseases 0.000 description 1
- 206010017711 Gangrene Diseases 0.000 description 1
- 208000005577 Gastroenteritis Diseases 0.000 description 1
- 206010018691 Granuloma Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010021027 Hypomagnesaemia Diseases 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 208000000913 Kidney Calculi Diseases 0.000 description 1
- 206010024612 Lipoma Diseases 0.000 description 1
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 1
- 206010026749 Mania Diseases 0.000 description 1
- 208000026139 Memory disease Diseases 0.000 description 1
- 206010029148 Nephrolithiasis Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 241000721454 Pemphigus Species 0.000 description 1
- 240000000513 Santalum album Species 0.000 description 1
- 235000008632 Santalum album Nutrition 0.000 description 1
- 241000447727 Scabies Species 0.000 description 1
- 206010048908 Seasonal allergy Diseases 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 206010067197 Tinea manuum Diseases 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 229930003779 Vitamin B12 Natural products 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 239000010975 amethyst Substances 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 230000010100 anticoagulation Effects 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 229910021383 artificial graphite Inorganic materials 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 210000000467 autonomic pathway Anatomy 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 208000028683 bipolar I disease Diseases 0.000 description 1
- 229940125690 blood glucose regulator Drugs 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000004097 bone metabolism Effects 0.000 description 1
- 230000003925 brain function Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000023852 carbohydrate metabolic process Effects 0.000 description 1
- 235000021256 carbohydrate metabolism Nutrition 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 201000001883 cholelithiasis Diseases 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 201000010989 colorectal carcinoma Diseases 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 230000001278 effect on cholesterol Effects 0.000 description 1
- 238000010891 electric arc Methods 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 210000000750 endocrine system Anatomy 0.000 description 1
- 208000030172 endocrine system disease Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000010437 erythropoiesis Effects 0.000 description 1
- 235000021112 essential micronutrients Nutrition 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- 210000004220 fundus oculi Anatomy 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 208000021302 gastroesophageal reflux disease Diseases 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 210000004209 hair Anatomy 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 150000002505 iron Chemical class 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 239000000891 luminescent agent Substances 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 208000004396 mastitis Diseases 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 230000006984 memory degeneration Effects 0.000 description 1
- 208000023060 memory loss Diseases 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000008558 metabolic pathway by substance Effects 0.000 description 1
- 208000015994 miscarriage Diseases 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 230000004118 muscle contraction Effects 0.000 description 1
- 201000008383 nephritis Diseases 0.000 description 1
- 229910052755 nonmetal Inorganic materials 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000011164 ossification Effects 0.000 description 1
- 230000004072 osteoblast differentiation Effects 0.000 description 1
- 230000001009 osteoporotic effect Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 244000138993 panchioli Species 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000008855 peristalsis Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 208000007442 rickets Diseases 0.000 description 1
- 229920002477 rna polymer Polymers 0.000 description 1
- 208000005687 scabies Diseases 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 230000036560 skin regeneration Effects 0.000 description 1
- 239000000917 skin toxin Substances 0.000 description 1
- 208000000995 spontaneous abortion Diseases 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229910003452 thorium oxide Inorganic materials 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 208000014001 urinary system disease Diseases 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 208000037911 visceral disease Diseases 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000019163 vitamin B12 Nutrition 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0052—Thermotherapy; Hyperthermia; Magnetic induction; Induction heating therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/244—Lanthanides; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N5/0613—Apparatus adapted for a specific treatment
- A61N5/0624—Apparatus adapted for a specific treatment for eliminating microbes, germs, bacteria on or in the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N5/0613—Apparatus adapted for a specific treatment
- A61N5/0625—Warming the body, e.g. hyperthermia treatment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N2005/0658—Radiation therapy using light characterised by the wavelength of light used
- A61N2005/0659—Radiation therapy using light characterised by the wavelength of light used infrared
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N2005/0658—Radiation therapy using light characterised by the wavelength of light used
- A61N2005/0661—Radiation therapy using light characterised by the wavelength of light used ultraviolet
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Inorganic Chemistry (AREA)
- Endocrinology (AREA)
- Pathology (AREA)
- Radiology & Medical Imaging (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Otolaryngology (AREA)
- Rheumatology (AREA)
- Oncology (AREA)
- Ophthalmology & Optometry (AREA)
- Communicable Diseases (AREA)
- Toxicology (AREA)
- Obesity (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Pain & Pain Management (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
一种医疗碳棒芯料组分,包括金属氧化物、氟硅酸盐、铁盐、钾盐、稀土金属和金属氟化物中一种或几种,其特征在于:氟硅酸钾的重量比为5‑15%,金属氧化物的重量比为34‑62%,金属氟化物的重量比为3‑23%,碳黑的重量比为3‑10%,石墨的重量比为10‑15%,金属铬的重量比为0‑4%,金属氯化物的重量比为0‑18%,艾精油的重量比为0‑5%,硫磺的重量比为0‑5%,碳酸锂的重量比为0‑5%。本发明在碳棒芯材中添加一定比例的人体必备微量元素或者中药硫磺、艾草精油,在一定程度上提高了碳棒的药理针对性。
Description
技术领域
本发明涉及医疗器械碳素光仪配件及其制备方法,特别是涉及一种用于医用碳棒芯料药物添加剂组分。
背景技术
光线疗法属于自然疗法,随着技术的不断发展,医学界、美容业对非药物的治疗方法越来越重视和看好。在许多的非药物治疗方法中,利用各种各样的光线(如红外线、紫外线、频谱、碳素光等)来防治人类的各种疾病已经较普遍地在临床中使用。国内申请号为200610048122.3,公开号为CN1911184A的发明专利公开了“一种医用碳棒及其制备方法”,该专利将含有金属氧化物、氟硅酸盐、铁盐、钾盐、稀土金属和金属氟化物的组分混合破碎,研磨成芯料,加入树脂粘结剂,形成药芯。专利号为98112394.5,公告号为CN1067287C的发明专利公开了一种“医药弧光治疗仪”,该专利在药物碳素棒中加入了中药非金属不燃矿物和可燃植物药,如紫石英、寒水石、生石膏、檀香、沉香、降香、艾叶等。专利号为87103603.7、公告号为CN87103603的发明专利公开了一种“人体频谱匹配效应场治疗装置及生产方法”,该专利将多种金属氧化物及稀土金属制成人体频谱发生层,产生作用于人体的频谱。在众多光线治疗设备中,惟有碳棒强弧产生的光线最接近于太阳光,为提高弧光的稳定性和亮度,现有技术中使用无机盐如钾盐、铁盐等提高电弧的稳定性,使用氟化稀土提高弧光的亮度(刘权,发光剂在弧光碳棒中的作用);使用氟硅酸钾来提高电弧的稳定性(黄建华、奚玲娣,电影放映碳棒负极芯料试验小结)。
现有技术虽然在碳棒芯材中加入不同的添加剂,均属于追求提高碳棒的发光强度和稳定性方面考虑。本发明在碳棒芯材中添加一定比例的人体必备微量元素或者中药硫磺、艾草精油,利用碳棒光辐射所产生的深部穿透热效应、光电效应和光化学效应,在一定程度上提高了碳棒的药理针对性。
发明内容
本发明解决的技术问题是,增强了碳棒的药理针对性。
本发明的技术方案为:一种医疗碳棒芯料组分,包括金属氧化物、氟硅酸盐、铁盐、钾盐、稀土金属和金属氟化物中一种或几种,其特征在于:氟硅酸钾的重量比为5-15%,金属氧化物的重量比为34-62%,金属氟化物的重量比为3-23%,碳黑的重量比为3-10%,石墨的重量比为10-15%,金属铬的重量比为0-4%,金属氯化物的重量比为0-18%,艾精油的重量比为0-5%,硫磺的重量比为0-5%,碳酸锂的重量比为0-5%。
进一步,所述金属氟化物的重量比为,氟化铈3-10%、氟化锂0-10%、氟化锶0-20%。
进一步,所述金属氧化物的重量比为,氧化钡4-8%,二氧化钍4-8%,氧化镁1-4%,氧化钼1-4%,氧化锌1-4%,氧化铬0-14%,氧化铁0-8%,三氧化二铁0-8%,氧化铜1-18%,氧化锶0-4%,氧化锰0-5%,氧化铷0-5%,氧化锂0-4%,氧化钴0-5%,氧化钙0-8%,氧化碘0-4%,氧化镧0-5%,氧化钪0-5%,氧化钒0-5%,氧化硒0-5%。
进一步,所述金属氯化物的重量比为,氯化锶0-18%,氯化钠0-12%,氯化铜0-12%。
具体实施方式
按照用途可将光线碳棒制成四种不同用途的医用碳棒。
氟硅酸钾用以提高电弧的稳定性,氟化铈、氧化钡、氧化钍用以增强发光强度,喷雾炭黑用以提高摩擦率,人造石墨用以芯料导电和降低电阻率,以上六种元素作为四种碳棒增强发光强度和保持弧光稳定的基础原料。
氧化镁是一种对许多身体功能(特别是肌肉和神经)都非常重要的天然矿物质,经常用于治疗十二指肠溃疡,消化不良,胃溃疡,胃食管返流性疾病,低镁血症,分泌紊乱,肾结石和便秘等疾病;氧化钼是七种重要微量营养元素之一。有研究表明,钼是第二、第三类过渡元素中已知唯一对人必不可少的元素,与同类过渡元素相比,钼的毒性极低,甚至可认为基本无毒。氧化锌可以维持人体正常食欲,增强人体免疫力;氧化铬同样是人体内必需的微量元素之一,它在控制血糖水平,保护心血管,控制体重,维持人体健康方面起关键作用。以上四种元素作为四种碳棒补充人体必备的共享元素。
根据不同用途的碳棒,加入下列不同用途的组分。
氧化锰,可促进骨骼的生长发育,保护细胞中线粒体的完整,保持正常的脑功能,维持正常的糖代谢和脂肪代谢,可改善机体的造血功能。
氧化碘,碘是人体的必需微量元素之一,有“智力元素”之称。氧化碘可以促进生物氧化,调节蛋白质合成和分解,促进糖和脂肪代谢,调节水盐代谢,促进维生素的吸收利用,增强酶的活力,维护中枢神经系统的正常结构。
氧化钴,通过产生红细胞生成进而促进骨髓造血。可促进肠粘膜对铁的吸收,加速贮存铁进入骨髓。通过维生素B12参与核糖核酸及造血物质的代谢,作用于造血过程。可促进脾脏释放红细胞,从而促进造血功能。
金属铬是人体内必需的微量元素之一,它在维持人体健康方面起关键作用。铬作为一种必要的微量营养元素在所有胰岛素调节活动中起重要作用,它能帮助胰岛素促进葡萄糖进入细胞内的效率,是重要的血糖调节剂。在血糖调节方面,特别是对糖尿病患者而言有着重要的作用。它有助于生长发育,并对血液中的胆固醇浓度也有控制作用,缺乏时可能会导致心脏疾病。铬还是葡萄糖耐量因子的组成成分,它可促进胰岛素在体内充分地发挥作用。达到对于有效预防并治疗组织内钙含量下降,骨质疏松、动脉硬化、高血压、糖尿病等成人疾病具有预防和治疗效果。还能够增强感染的抵抗力,对过敏性疾病及花粉症有效。此外,还有益于对大肠癌及乳腺炎的预防。
氧化锶对成骨细胞分化和骨生成促进作用。另外,在骨质疏松动物模型中,锶可改善骨代谢,预防骨丢失,提高骨质疏松动物的骨质量。锶元素的适量掺入可提高骨质的机械性能,从而改善骨的机械强度。在心血管疾病方面,锶能减少人体对钠的吸收,故有预防心血管疾病的作用。在皮外适量补充锶有助皮肤再生、修复细胞,促进皮肤新陈代谢,同时会提高皮肤抗氧化能力及免疫能力,帮助皮肤排出毒素。
氧化锂能改善造血功能,提高人体免疫机能。锂对中枢神经活动有调节作用,能镇静、安神,控制神经紊乱。锂可置换替代钠,防治心血管疾病。锂是有效的情绪稳定剂。是治疗急性躁狂症和躁狂-抑郁病预防性管理的最有效措施。同时,达到熔点会产生氧气,可以改善碳棒使用环境。
氧化铁是红细胞成熟过程中合成血红蛋白必不可少原料。主要以铁蛋白的式储存在肝、脾和骨髓中。其中妇女是需要补充铁元素的特别人群。
氧化钙可以控制心率和血压,也参与肌肉的收缩活动。有助于控制高血压和冠心病,有效地预防骨质酥松,尿路结石、结(直)肠癌。
氧化铜,铜是人体健康不可缺少的微量营养素之一,对于血液、中枢神经和免疫系统,头发、皮肤和骨骼组织以及脑子和肝、心等内脏的发育和功能有重要影响。
氧化铷,铷对人类健康具有积极意义。有模拟钾的生物效应,可部分替代钾的生理功能;铷摄入量降低会导致脑衰老、生长缓慢、生育率降低、流产增加;抑郁症、早老性痴呆、失忆等神经性疾病均与铷含量的不正常变化相关。目前,国内外动物试验均证实,铷能明显地抑制肿瘤生长。铷进入细胞膜与钾离子竞争并占有优势,因此降低了细胞液中钾离子和由钾离子携入的葡萄糖,从而减少病变细胞或肿瘤细胞内的营养,致其凋亡。
艾精油具有抗菌及抗病毒作用;平喘、镇咳及祛痰作用;止血及抗凝血作用;镇静及抗过敏作用;护肝利胆的作用。增强人体对疾病的抵抗能力的作用。
碳酸锂,锂能改善造血功能,提高人体免疫机能。锂对中枢神经活动有调节作用,能镇静、安神,控制神经紊乱。锂是有效的情绪稳定剂,碳酸锂治疗的临床研究表明,锂的主要反应器官为胃肠道、肾脏、神经、肌肉、内分泌和心血管系统。
氧化钪、氧化镧、氧化硒、氧化钒:具有抗癌作用
三氧化二铁,铁是红细胞成熟过程中合成血红蛋白必不可少原料。主要以铁蛋白的式储存在肝、脾和骨髓中。其中妇女是需要补充铁元素的特别人群。
硫磺:具有收湿止痒的功效,补火壮阳通便,用于肾虚喘息、阳痿及虚冷便秘。治下元虚冷之喘息,解毒杀虫止痒,用于湿疹、疥癣、疥疮,秃疮、可治一切干湿癣。
实施例1:标准光
所谓标准光是因为该碳棒红外线、可见光和紫外线基本是均等的放射,在使用过程中,该碳棒是与其他碳棒组合使用的碳棒(如果是日常保健亦可单独使用)。为此,特增加了以下组份,氧化锰、氧化碘、氧化钴、金属铬、氧化锶、氧化锂、氧化钙。为便于目测区分碳棒光谱,特在芯料使用上加入焰火级氧化铜或氯化钡。
实施例2:红外线光
红外线穿透性强,具有在体内将热能转换为深部温热的作用,在镇痛、消炎、舒筋及改善局部循环方面有显著的疗效。同时,还具有调整物质代谢的亢进及肠胃蠕动运动,解毒,促进病灶吸收,仰制细菌繁殖等多种作用。组份中增加氧化铜、氧化铁、氧化锶、氧化铷、艾精油。为便于目测区分碳棒光谱,特在芯料中加入氯化锶增强红色光谱。
实施例3:可见光
因其具有深透的温热作用和光化学作用,主要适应内脏疾病,代谢性疾病,自律神经以及内分泌系统疾病。特加入具有防癌治癌作用的氧化钪、氧化镧、氧化硒、氧化铷、氧化钒五种元素。对新陈代谢,组织再生,肿块及硬结的吸收,镇痛、消炎等具有有效作用。对肠胃炎、十二指肠溃疡、肝炎、肝硬化、胆结石、胰腺炎、溃疡性大肠炎、肾炎、泌尿系统疾病、耳鼻喉科疾病、眼科疾病(特别是眼底疾病)、妇科疾病等均有效果。组份还增加碳酸锂、氧化钴、氧化铜、氧化铁、氧化锰、金属铬。为便于目测区分碳棒光谱,特在芯料中加入氯化钠增强黄色光谱。
实施例4:紫外线光
紫外线疗法的应用是最古老而普遍的。因为紫外线有强烈的杀菌作用,它破坏细菌的代谢,使细菌变性而死亡。所以紫外线的抗菌、消炎作用不亚于抗菌素,治疗皮肤、粘膜的炎症(包括特异性和非特异性炎症),特别是化脓性、坏疽性疾病优于抗菌素,疗效快、无毒副作用。紫外线还有较好的抗佝偻病作用,同时尚有抗过敏作用和生成钙吸收所必需的维生素D,增强人体免疫功能,提高抗病能力。对于皮肤病、化脓性感染、表皮再生、肉芽生成、肉芽肿的吸收、白班、癣、掌脓胞症、恶性圆形脱毛症、久治不愈的阿托品性皮炎、湿疹、天疱疮、狐臭、烧伤、脂肪瘤等均有效果。组份中增加氧化钙、氧化铜、三氧化二铁、氧化锰、金属铬、氧化锶、硫磺。为便于目测区分碳棒光谱,特在芯料中加入氯化铜增强兰色光谱。
Claims (8)
1.一种医疗碳棒芯料组分,包括金属氧化物、氟硅酸盐、铁盐、钾盐、稀土金属和金属氟化物中一种或几种,其特征在于:氟硅酸钾的重量比为5-15%,金属氧化物的重量比为34-62%,金属氟化物的重量比为3-23%,碳黑的重量比为3-10%,石墨的重量比为10-15%,金属铬的重量比为0-4%,金属氯化物的重量比为0-18%,艾精油的重量比为0-5%,硫磺的重量比为0-5%,碳酸锂的重量比为0-5%。
2.如权利要求1所述的一种医疗碳棒芯料组分,其特征在于:氟硅酸钾的重量比为10-13%,碳黑的重量比为5%,金属氟化物的重量比为6-21%。
3.如权利要求1所述的一种医疗碳棒芯料组分,其特征在于:所述金属氟化物的重量比为,氟化铈3-10%、氟化锂0-10%、氟化锶0-20%。
4.如权利要求3所述的一种医疗碳棒芯料组分,其特征在于:所述氟化铈的重量比为6%。
5.如权利要求1所述的一种医疗碳棒芯料组分,其特征在于:所述金属氧化物的重量比为,氧化钡4-8%,二氧化钍4-8%,氧化镁1-4%,氧化钼1-4%,氧化锌1-4%,氧化铬0-14%,氧化铁0-8%,三氧化二铁0-8%,氧化铜1-18%,氧化锶0-4%,氧化锰0-5%,氧化铷0-5%,氧化锂0-4%,氧化钴0-5%,氧化钙0-8%,氧化碘0-4%,氧化镧0-5%,氧化钪0-5%,氧化钒0-5%,氧化硒0-5%。
6.如权利要求5所述的一种医疗碳棒芯料组分,其特征在于:所述金属氧化物的重量比为,氧化钡6%,二氧化钍6%,氧化镁2-3%,氧化钼2-3%,氧化锌2-3%,氧化铬1-12%,氧化铜3-15%。
7.如权利要求5所述的一种医疗碳棒芯料组分,其特征在于:所述氧化铜为焰火级氧化铜。
8.如权利要求1所述的一种医疗碳棒芯料组分,其特征在于:所述金属氯化物的重量比为,氯化锶0-18%,氯化钠0-12%,氯化铜0-12%,氯化钡0-18%。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010220737.XA CN111265661A (zh) | 2020-03-26 | 2020-03-26 | 一种医疗碳棒芯料组分 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010220737.XA CN111265661A (zh) | 2020-03-26 | 2020-03-26 | 一种医疗碳棒芯料组分 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN111265661A true CN111265661A (zh) | 2020-06-12 |
Family
ID=70991759
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010220737.XA Pending CN111265661A (zh) | 2020-03-26 | 2020-03-26 | 一种医疗碳棒芯料组分 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN111265661A (zh) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1229684A (zh) * | 1998-03-19 | 1999-09-29 | 曾小平 | 医药弧光治疗仪 |
CN1911184A (zh) * | 2006-08-08 | 2007-02-14 | 程永起 | 一种医用碳棒及其制备方法 |
CN203598368U (zh) * | 2013-09-11 | 2014-05-21 | 王建国 | 全自动碳素光治疗机 |
-
2020
- 2020-03-26 CN CN202010220737.XA patent/CN111265661A/zh active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1229684A (zh) * | 1998-03-19 | 1999-09-29 | 曾小平 | 医药弧光治疗仪 |
CN1911184A (zh) * | 2006-08-08 | 2007-02-14 | 程永起 | 一种医用碳棒及其制备方法 |
CN203598368U (zh) * | 2013-09-11 | 2014-05-21 | 王建国 | 全自动碳素光治疗机 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5814078A (en) | Method and apparatus for regulating and improving the status of development and survival of living organisms | |
JPH06339537A (ja) | 生物の生長と生存状態を調節し改善する方法および装置 | |
CN110141750A (zh) | 一种多用途广谱治疗仪 | |
CN109172491A (zh) | 一种具有抗衰老和活血化瘀功能的霜剂及其制备方法 | |
CN106038229A (zh) | 一种火沙理疗外用组合物及其应用 | |
CN111265661A (zh) | 一种医疗碳棒芯料组分 | |
CN101953971A (zh) | 养身酒 | |
KR20090118175A (ko) | 천연광물 또는 산화금속으로부터 미네랄의 분리 및미네랄수의 제조방법 | |
JP2017203018A (ja) | 栄養飲料水、動物性・植物性食物の栄養素を体内の細胞に与え、頭皮には混合育毛液を併用した、賦活による育毛法。 | |
CN105770040A (zh) | 药石敷穴磁疗自热袋 | |
CN1025652C (zh) | 癌克口服液及其配制方法 | |
CN103932941A (zh) | 营养元素抗衰护肤液 | |
KR101326720B1 (ko) | 생약처리된 미네랄 워터 조성물 및 그 제조방법 | |
CN103349276A (zh) | 蛇粉松树针系列提取物元素胶囊 | |
CN1541568A (zh) | 海参片及其制备方法 | |
CN1730006A (zh) | 一种治疗肺肾两虚、气阴不足的药物组合物及其制备方法 | |
CN108464416A (zh) | 天然排毒抗氧化保健饮料 | |
Pradhan et al. | Conceptual review on Sasyaka (tuttha) | |
CN106924059A (zh) | 营养元素维生素抗衰护肤纳米乳液 | |
CN2540189Y (zh) | 光能睡眠调节仪 | |
Kakar et al. | The relationship between cancer, radiotherapy and vitamin C | |
RU2149041C1 (ru) | Способ реабилитации больных, радикально оперированных по поводу рака желудка и с пострезекционными нарушениями | |
SU1163856A1 (ru) | Способ лечени больных экземой | |
Pakdaman | Oxygen Enriched Water and Oral Oxygen Therapy (OOT) | |
CN1895523A (zh) | 调控基因核能核酸口服液及制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WD01 | Invention patent application deemed withdrawn after publication | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20200612 |